IL-32 and IL-34 in hepatocellular carcinoma

Yang Si; Jiwei Zhang; Shisan Bao; Steven G Wise; Yuli Wang; Yanfang Zhang; Yuhong Tang

doi:10.3389/fmed.2022.1051113

IL-32 and IL-34 in hepatocellular carcinoma

Front Med (Lausanne). 2022 Nov 11:9:1051113. doi: 10.3389/fmed.2022.1051113. eCollection 2022.

Authors

Yang Si¹, Jiwei Zhang², Shisan Bao², Steven G Wise³, Yuli Wang¹, Yanfang Zhang¹, Yuhong Tang¹

Affiliations

¹ Department of Hematology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
² Department of Cardiothoracic Surgery, Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine (Preparatory Stage), Shanghai, China.
³ Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.

Abstract

Hepatocellular carcinoma (HCC) remains a major challenge to clinicians due to its unacceptably high mortality and morbidity. The etiology of HCC is multi-faceted, including viral infection, alcoholism and non-alcoholic fatty liver disease. Dysregulated host immunity contributes to tumorigenesis among these susceptible individuals with pre-existing condition(s). IL-32 and IL-34 are key cytokines driving the development of chronic inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, as well as chronic liver diseases. IL-32 and IL-34 play an important role augmenting the development of HCC, due to their direct influence over host inflammation, however, new roles for these cytokines in HCC are emerging. Here we comprehensively review the latest research for IL-32 and IL-34 in HCC, identifying a subset of potential therapeutic targets for use in precision medicine.

Keywords: IL-32; IL-34; biomarkers; gastrointestinal; hepatocellular carcinoma.

Publication types

Review